Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Targeted Protein Degradation and Neurological/Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MIDN (Midnolin) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MIDN Full-Length & Catch Domain Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View MIDN Products |
| Gene Delivery | MIDN Promise-ORF / Lentivirus Full-length ORF, codon optimized, with selection marker for stable cell lines. |
View MIDN Products |
| Benchmark Antibody | Anti-MIDN Recombinant Antibody Recombinant positive control for assay benchmarking, Western blot, IHC, and IP. |
View MIDN Products |
| Validator | MIDN siRNA Set (3 unique targets) For knockdown verification and assay specificity control. |
View MIDN Products |
| Complex Partner (Optional) | CRBN-DDB1-Cul4A Components Recombinant E3 ligase machinery for ternary complex assays (if applicable). |
View CRBN Products |
| Related Target | EGR1 Direct binding substrate of MIDN for proteasomal degradation. |
View EGR1 Products |
| Related Target | FOS (c-Fos) Immediate early gene degraded via the MIDN pathway. |
View FOS Products |
| Related Target | MYC Transcription factor substrate of the Midnolin-proteasome degradation axis. |
View MYC Products |
| Related Target | IKZF1 (Ikaros) Transcription factor substrate potentially degraded via MIDN pathway. |
View IKZF1 Products |
| Related Target | GSPT1 Parallel CRBN neosubstrate; off-target liability screening. |
View GSPT1 Products |
| Related Target | PSMA1 Proteasome core subunit for selectivity counter-screening. |
View PSMA1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Validating Protein-Protein Interactions (PPI) / Ternary Complex Formation | High-purity MIDN Catch Domain & full-length proteins (>95%) verified by SPR/BLI; native folding for true binding kinetics. |
| Cellular Overexpression & Intracellular Target Engagement | MIDN Lentivirus (CMV promoter) for stable overexpression; sequence-verified, validated in HEK293 and cancer cell lines. |
| Lack of Reliable Controls & Assay Specificity | Recombinant Benchmark Antibody (lot-to-lot consistent) + Validated siRNA set for orthogonal validation. |
| Off-Target / Subfamily Specificity | Counter-screen panels including IKZF1/3, GSPT1, and PSMA1; mass spec-verified to exclude cross-contamination. |
| Cross-Species Evaluation (Mouse/Cyno) | Human, Mouse, and Cyno MIDN ortholog proteins available (>95% purity); sequence alignment verified for epitope conservation. |
| Drug Resistance Mutation Screening | Custom mutant MIDN variants (hotspot domains) for mechanistic studies; alanine scanning libraries available. |
Live MIDN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The discovery of MIDN (Midnolin) as a ubiquitin-independent mechanism for targeting transcription factors to the proteasome has opened new avenues in targeted protein degradation. MIDN directly captures substrates such as EGR1, c-Fos, and MYC via its unique Catch domain and delivers them to the proteasome for degradation. This mechanism is implicated in neurodegenerative disorders (e.g., Parkinson's disease) and oncology. Current R&D focuses on small-molecule PPI inhibitors, molecular glues, and PROTACs that modulate the MIDN-substrate interaction. The next wave aims to exploit the Catch domain for selective degradation of oncogenic transcription factors while sparing essential factors to reduce toxicity. Co-option of MIDN by molecular glues (e.g., IMiDs) is also under investigation for expanding the therapeutic index of existing agents.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Modulators (PPI inhibitors) | Academic Consortia, Early Biotech, TPD-Focused Biotechs | Parkinson's Disease, Neurological, Solid Tumors | PPI validation assay using high-purity MIDN protein for SPR/BLI. |
| Molecular Glues / PROTACs | Bristol Myers Squibb, Celgene, Arvinas, C4 Therapeutics | Multiple Myeloma, MDS, Refractory Solid Tumors | Ternary complex formation assay (MIDN-substrate-proteasome); domain mapping reagents. |
| Genetic Modulation (siRNA / Overexpression) | Research Institutions, Functional Genomics Consortia | Mechanism of Disease Validation, Proteostasis Disorders | Lentivirus and validated siRNA for target engagement confirmation. |
| Biologics / Intracellular Antibody Fragments | Emerging Biotech Platforms, Academic Consortia | Refractory Cancers, Proteinopathy | Full-length MIDN antigen for specificity screening and off-target panel. |